NextFin News -
1) Pre-Market Performance
U.S. equity-index futures are modestly higher ahead of the open, with growth shares showing the firmest bid. Nasdaq 100 futures are up 83.8 points, or 0.28%, to 30,136.5; S&P 500 futures are up 10.0 points, or 0.13%, to 7,510.3; and Dow futures are up 40 points, or 0.08%, to 52,612.
European equities are broadly positive: DAX up 381.37 points, or 1.55%, to 25,008.26; FTSE 100 up 104.42 points, or 1.00%, to 10,588.64; CAC 40 up 42.71 points, or 0.51%, to 8,410.04.
Commodity and currency markets are firmer: Brent crude around $74.45 (up $0.54, or 0.73%); WTI crude around $71.21 (up $0.46, or 0.65%); Gold futures up $8.32, or 0.21%, to $4,047.22; and the U.S. Dollar Index higher by 0.283, or 0.28%, to 101.16.
2) Hot News
- Quarter-end tone remains constructive. U.S. futures are edging higher after Monday’s rebound, with investors balancing recent tech volatility against a still-resilient broader equity backdrop and continued demand for growth and AI-linked exposure.
- Energy markets stay focused on U.S.–Iran talks. Oil remains sensitive to headlines around a strained interim ceasefire and potential talks in Doha, keeping energy, transport and inflation-sensitive groups in focus.
- European markets rally into the U.S. open. The DAX, FTSE 100 and CAC 40 are all higher, supporting global risk sentiment heading into the U.S. session.
- Pre-market dispersion is elevated. Earnings beats, drug-review updates, capital raises and large corporate actions are creating sharp single-stock moves, pointing to a stock-specific session rather than a purely index-driven open.
- Bank stocks pressured after brokerage downgrade. Oppenheimer downgraded major Wall Street investment banks, with Goldman Sachs indicated about 0.5% lower and Morgan Stanley about 1.2% lower in pre-market trading.
3) U.S. Stock Focus
- AeroVironment — Q4 beat drives sharp pre-market rally. Shares are up about 21.4% to $168.70 after stronger-than-expected fiscal fourth-quarter results; fiscal 2027 revenue guided to $2.13 billion to $2.23 billion and adjusted EPS guidance $3.02 to $3.34.
- Concentrix — guidance cut pressures shares. Down about 24% to $19.19 after lowering fiscal 2026 revenue to $9.93 billion to $10.03 billion and adjusted EPS to $10.83 to $11.18.
- Praxis Precision Medicines — FDA extends relutrigine review. The FDA extended the review period by three months, moving the PDUFA target action date to December 27, 2026 from September 27, 2026, and shares traded lower.
- Vishay Intertechnology — $750 million equity offering weighs on stock. Down about 8.4% to $51.57 after pricing 15.0 million shares at $50 per share, with underwriters granted a 30-day option to buy up to 2.25 million additional shares.
- Abivax — ulcerative colitis data lifts ADRs. ADRs are up about 33.7% to $128.59 after positive ABTECT Maintenance Part 2 results for obefazimod, with 37.2% of induction non-responders achieving clinical remission and 34.5% endoscopic remission at Week 44.
- Mama’s Creations — stock falls after offering pricing. Down about 11% to $18.39 after pricing 5,555,556 shares at $18.00 per share, expecting approximately $100 million gross proceeds.
- Nvidia — Indonesia AI-infrastructure project keeps AI demand in focus. Nvidia was indicated higher after plans for a major AI data-center campus in Batam, Indonesia, including a planned 170,000-GPU deployment and a 360MW campus.
- Alphabet — Dow debut reinforces mega-cap tech influence. Alphabet climbed after debuting in the Dow Jones Industrial Average, increasing the index’s exposure to digital advertising, cloud and AI-linked businesses.
Explore more exclusive insights at nextfin.ai.
